Candida albicans is known for its ability to form biofilms, which are communities of microorganisms embedded in an extracellular matrix developing on different surfaces. Biofilms are highly tolerant to antifungal therapy. This phenomenon has been partially explained by the appearance of so-called persister cells, phenotypic variants of wild-type cells, capable of surviving very high concentrations of antimicrobial agents. Persister cells in C. albicans were found exceptionally in biofilms, while none were detected in planktonic cultures of this fungus. Yet, this topic remains controversial, as others could not observe persister cells in biofilms formed by the C. albicans SC5314 laboratory strain. Due to ambiguous data in the literature, this work aimed to reevaluate the presence of persister cells in C. albicans biofilms. We demonstrated that the isolation of C. albicans "persister cells" as described previously was likely to be the result of the survival of biofilm cells that were not reached by the antifungal. We tested biofilms of SC5314 and its derivatives, as well as 95 clinical isolates, using an improved protocol, demonstrating that persister cells are not a characteristic trait of C. albicans biofilms. Although some clinical isolates are able to yield survivors upon the antifungal treatment of biofilms, this phenomenon is rather stochastic and inconsistent.
albicans, which could contribute to biofilm tolerance to antifungals (8) . In their paper, the authors reported that C. albicans exhibits a biphasic killing curve when exposed to antifungals such as amphotericin B (AMB), chlorhexidine, or a combination of both. This phenomenon is explained by the presence of a multidrug-tolerant subpopulation of persister cells within a biofilm, while planktonic cultures of C. albicans were found to be devoid of persisters. Notably, the experiments for this study were performed using an in vitro biofilm model of C. albicans developed in polystyrene 96-well plates. Following this work and relying on the protocol for persister cells isolation described therein (8) , persister cells in C. albicans biofilms were described by a few other groups (14) (15) (16) . However, later work by Al-Dhaheri and Douglas showed that not all Candida species and strains were able to form persister cells in laboratory-grown biofilms (17) . This was in particular the case for C. albicans strain SC5314 (18) , the parental strain of almost all C. albicans strains used for functional genomics and molecular genetics studies. Unlike in the previously mentioned papers (8, (14) (15) (16) , the protocol Al-Dhaheri and Douglas (17) used for persister isolation involved growing biofilms on silicone discs, followed by their immersion into an antifungal solution. As the topic of C. albicans persister cells remains controversial, the main objective of this work was to reevaluate their occurrence in in vitro-grown C. albicans biofilms.
RESULTS AND DISCUSSION
In this work, we aimed to study the occurrence of persister cells in C. albicans biofilms. We applied the protocol published by LaFleur and colleagues, growing the biofilms in RPMI medium and in a 96-well plate format (8) . We set up the protocol with 3 C. albicans prototroph strains, namely SC5314, CEC369, and CEC4664; CEC369 and CEC4664 are prototroph derivatives of BWP17 (19) and SN76 (20) , respectively. BWP17 and SN76 are independent auxotroph derivatives of SC5314.
We encountered a technical problem at the biofilm recovery step, usually performed by scraping the cells in 1ϫ phosphate-buffered saline (PBS) and vortexing prior to plating (8, 14, 16, 21) . In our hands, the cells could not be properly resuspended and plated, as clumps of the biofilms would usually remain stranded inside the tips. Consequently, the CFU numbers obtained were highly varied for all samples, making any further analysis and comparison impossible (data not shown).
We decided to test alternative approaches to circumvent the stickiness of biofilms. Resuspending cells in 20% glycerol-1ϫ PBS for plating helped reduce stickiness but did not improve consistency (data not shown). We hypothesized that EDTA might reduce the adherence of biofilms by binding bivalent cations that are required for the activity of cell surface adhesins (22) . Thus, we attempted applying 20% glycerol with a range of EDTA concentrations (0, 50, and 100 mM) for plating. One hundred microliters of EDTA solutions of different concentrations was added to biofilms and left for 10 min at room temperature prior to biofilm disruption by scraping and vortexing. None of the applied EDTA solutions allowed abolishment of stickiness. Additionally, colonies growing on yeast-peptone-dextrose (YPD) agar exhibited a wrinkled morphology, most probably linked to the toxicity of EDTA (23) . Finally, we tried adding Tween 20 (0.05%) to PBS. Tween 20 eradicated the problems of stickiness and poor disruption and improved the recovery of cells from the biofilms (Fig. 1) . The effect on cell viability was tested using a planktonic culture of SC5314 that was washed and plated on YPD agar using PBS and PBS-Tween 20 solutions. No impact on viability was observed (data not shown). Thus, in the experiments described below, biofilms were resuspended in a 0.05% Tween 20-1ϫ PBS solution.
However, even after this modification, the ratios of cells that survived AMB treatment were still inconsistent between repeats. According to LaFleur and colleagues, the ratios of C. albicans persister cells in biofilms vary from 0.1% to 2% for different strains, notably from 0.05 to 0.1% for strain CAI4, a derivative of C. albicans SC5314 (8) . Our values hardly ever exceeded 0.01% persisters per biofilm, even after improving the recovery protocol, thus bordering with statistical error. We reasoned that increasing the surface of a biofilm and changing the growth medium could improve persister yields, and we decided to test the protocol described in reference 14, applying the modifications that were mentioned previously. However, the problems of inconsistency and low ratios of persisters remained (Fig. 2 ).
In all protocols described previously, the volumes of the medium and solutions used for biofilm growth, washing, and AMB treatment were identical. Upon careful observation, we noticed that C. albicans cells form a dense rim at the border of the air and liquid phases as a result of agitation during growth. Treating a biofilm with the exact FIG 1 Effect of Tween 20 on the recovery of CFU from C. albicans SC5314 biofilms. C. albicans SC5314 was allowed to form biofilms in 100 l RPMI medium in a 96-well plate according to the protocol adapted from LaFleur et al. (8) . Error bars indicate the standard deviation (SD) of the results from 6 biological replicates generated from 2 independent experiments. #, nonsignificant difference; ***, significant difference (P ϭ 0.0007; unpaired t test was applied to compare data sets).
FIG 2
Schemes of the protocols (A) and levels of persisters (B) obtained from biofilms grown using modified protocol from Li et al. (14) . Biofilms were grown in 1 ml of GHAUM medium in 24-well plates before application of either 1 ml of AMB solution (left) or 3 ml of AMB solution (right). Ratios of surviving cells are as follows: SC5314, 5.6 ϫ 10 Ϫ4 %; CEC369, 2.6 ϫ 10 Ϫ5 %; and CEC4664, 9.4 ϫ 10 Ϫ5 %. Error bars indicate the SD of the results from 6 biological replicates generated from 2 independent experiments.
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Antimicrobial Agents and Chemotherapy same volume of antifungal and growth medium under static conditions thus could result in cells from the rim escaping treatment. We decided to increase the volume of the applied antifungal solution (filling wells to the top), and, to our surprise, this change in the protocol led to a complete eradication of persisters for the laboratory strain SC5314 and its derivatives. Reproducibly, we did not obtain any persisters after applying this change for all strains for biofilms grown in both RPMI and GHAUM (Sabouraud dextrose [SD] supplemented with 2% glucose and 1 mg/ml histidine, 1 mg/ml arginine, 0.02 mg/ml uridine, and 2 mg/ml methionine) media. Thus, the volume of the antifungal applied in the original protocols for persister isolation was skewing the results. Increasing the volume of antifungal eliminated this bias, resulting in a complete eradication of any survivors after the antifungal treatment.
In our work, we used a modified protocol for persister cell isolation with a starting cell suspension of an optical density at 600 nm (OD 600 ) of 0.3 used for biofilm growth instead of 0.1 as described in the original protocols (8, 14) . To assess the impact of the initial cell number used for seeding biofilms on persister cells' appearance, we tested our protocol for SC5314 using cell suspensions at an OD 600 of 0.1, 0.3, and 0.5 for seeding. Regardless of the initial biomass, persister cells did not form in SC5314 biofilms grown either in RPMI or GHAUM medium (data not shown).
These results made us question the very existence of persister cells in C. albicans biofilms. Previously, Al-Dhaheri and Douglas showed that not all strains of C. albicans can form persister cells (17) . Particularly, in their hands, SC5314 biofilms lost all viability after exposure to 30 g/ml AMB. However, biofilms of another clinical isolate, GDH2346, appeared to contain a small proportion (0.01%) of cells that survived 100 g/ml AMB treatment. These authors used a different in vitro model for assessing persistence, as they grew biofilms on silicone discs that were transferred to a new well filled with an antifungal solution. This prevented the escape of any cells from the antifungal treatment. Thus, our modified protocol for the treatment of biofilms formed in 96-well or 24-well plates corroborated the results obtained by the Douglas group for C. albicans strain SC5314 (17) .
Since the clinical isolate GDH2346 could give rise to survivors (17), we could not exclude that persisters could emerge in biofilms of different C. albicans isolates. Additionally, in 2010, LaFleur and colleagues isolated and described C. albicans strains from patients with long-term oral infection that gave yield to increased levels of persisters (up to 8.9%) (21) . These were called hip mutants, by analogy with the high-persister strains previously described for bacteria (24, 25) . Although hip mutants were identified using a protocol that showed limitations in our hands, we hypothesized that some C. albicans clinical isolates could generally be more prone to form persisters than others (namely SC5314). To test this assumption, we tested 95 clinical isolates (see Table S1 in the supplemental material) for their ability to form biofilms and for the occurrence of persister cells following AMB treatment. In a first round of experiments, biofilms were treated with a 64 g/ml AMB solution. Only 38 isolates (39.6%) displayed survivors (notably, never exceeding a rate of 0.02%). According to the generally accepted concept of persistence (10), the frequency of persisters' appearance is independent of the increase in antibiotic concentration. Thus, in a second round of experiments, biofilms were developed for these 38 isolates and treated with a 100 g/ml AMB solution. Notably, only 7 isolates out of these 38 displayed survivors when grown with 100 g/ml AMB (CEC3622, CEC3668, CEC3669, CEC4514, CEC4521, CEC5317, CEC5318). These 7 strains, together with 4 other isolates randomly picked in the remaining 31 strains (CEC712, CEC3708, CEC3711, and CEC5316), were tested seven more times with 100 g/ml AMB. In most cases, these strains did not yield persister cells (Fig. 3) ; however, 7 strains (CEC3622, CEC3669, CEC4514, CEC4521, CEC5316, CEC5317, and CEC5318) gave rise to small numbers of survivors in 1 to 4 of the experiments (Fig.  3) , with the survival rate never exceeding 9.1 ϫ 10 Ϫ4 % per biofilm (for CEC3622). This could be explained either by the stochastic nature of persistence as a phenomenon or by technical errors during the experiment.
We tested up to 30 randomly picked colonies for three isolates (CEC3622, CEC4514, and CEC5316) on yeast-nitrogen-glucose (YNG) medium containing 10 g/ml AMB. None of the tested colonies were able to grow in the presence of amphotericin B (data not shown), proving that their survival was not a result of AMB resistance development.
With an improved protocol in our hands, we decided to test other Candida species for their ability to form persister cells in biofilms. Previously, Al-Dhaheri and Douglas (17) reported that clinical isolates of Candida krusei (Glasgow strain) and Candida parapsilosis (AAHB 4479) developed persister cells in biofilms (approximately 0.001% and 0.07%, respectively) upon treatment with 100 g/ml AMB. We selected 3 clinical isolates of Candida tropicalis (CEC5296, CEC5297, and CEC5298) and 3 of C. parapsilosis (CEC5299, CEC5300, and CEC5301) from our lab collection to test with our protocol. One of the C. tropicalis strains (CEC5298) and the 3 selected C. parapsilosis strains were unable to grow as biofilms and were excluded from the study. C. tropicalis CEC5296 and CEC5297 formed proper biofilms, with a small fraction of persisters ranging from 2 ϫ 10 Ϫ5 to 6.4 ϫ 10 Ϫ3 % and 2.3 ϫ 10 Ϫ7 to 2.6 ϫ 10 Ϫ4 %, respectively (data not shown). Such low values are comparable to the survival rates we observed for some of the C. albicans clinical isolates tested in this study. As before, we cannot exclude that these survivors are persister cells arising within C. tropicalis biofilms or that they are the consequence of a technical error during the experiment.
Since 1944, when Bigger first described persister cells in Staphylococcus spp. (9), many advances have been made in exploring this phenomenon, especially in bacteria. It is known that microbial cultures growing in vivo can sometimes be very difficult to eradicate completely by an antibiotic treatment, causing relapses or development of chronic infections in patients. From an evolutionary point of view, a small pool of cells with the same genotype as the rest of the population but differing in their ability to tolerate stress, including drug treatment, provides a form of insurance to the population.
The phenomenon of persistence has not only been described for bacteria, but also in other types of pathogens, and it has been proposed that persister cells significantly contributed to the recalcitrance of C. albicans biofilms to antifungal treatments (26) (27) (28) .
C. albicans persister cells were first described in 2006 (8) , and since then, only a few reports, sometimes contradictory, have been presented. In our study, we explored standard protocols to obtain persisters and showed that their proportion in biofilms formed by different C. albicans strains has been overestimated. Only Al-Dhaheri and Douglas did not detect persisters in SC5314 biofilms (17) . In their study, biofilms were grown on silicon discs that were transferred in antifungal solutions for treatment. In contrast, the other published experiments were performed using 96-well plates and RPMI medium or 24-well plates and SD-based medium, while keeping the incubation volumes constant throughout the experiment (8, (14) (15) (16) . In this study, we modified the [14] ). The values obtained from 7 biofilms were used to draw the graph.
Antimicrobial Agents and Chemotherapy protocols growing biofilms at the bottom of 96-or 24-well plates (8, (14) (15) (16) by increasing the volume of antifungal. This change led to the eradication of biofilms, indicating that previously detected "persisters" were likely the result of survival of cells that were not reached by the antifungal. Our results corroborate the findings of Al-Dhaheri and Douglas (17) . Notably, these authors were able to detect some persisters in biofilms of a clinical isolate (17) , but the ratio obtained was much lower (0.01%) than the numbers published by others (8, 14) . Although some of the clinical isolates of C. albicans and C. tropicalis tested in our study were occasionally able to yield survivors after the treatment of biofilms with AMB, this phenomenon was rather inconsistent, pointing either to the stochastic nature of persistence itself or to another skew in the protocol while carrying out particular experiments.
At this time, we cannot completely exclude the possibility of persistence in all C. albicans strains, though with the described protocol, we managed to disprove their presence for 92 C. albicans strains out of 98. It is important to stress that our results reflect only the behavior of C. albicans biofilms grown in vitro; we cannot rule out that in the context of the host, persister cells could appear and contribute to the general resistance and dissemination of C. albicans.
MATERIALS AND METHODS
Strains and growth conditions. In this study, we used 3 reference strains (listed in Table 1 ) and a set of 95 C. albicans (Table 2 ), 3 C. tropicalis, and 3 C. parapsilosis clinical isolates.
Yeast precultures were grown overnight in YPD (1% yeast extract, 2% peptone, 2% glucose) agar with shaking at 30°C.
Biofilms were grown either in RPMI 1640 medium with L-glutamine (buffered with 50 mM HEPES), as described previously (8, 29) , or in GHAUM medium (SD supplemented with 2% glucose and 1 mg/ml histidine, 1 mg/ml arginine, 0.02 mg/ml uridine, and 2 mg/ml methionine [30] ).
Resistance was checked on solid YNG (6,7 g/liter yeast nitrogen base without amino acids and with ammonium sulfate, 2% glucose, and 2% agar) medium supplemented with 10 g/ml AMB.
Biofilm growth and persister cell isolation. To assess persister cell appearance in biofilms, we used two protocols adapted either from LaFleur et al. (8) or Li et al. (14) . The first protocol uses 96-well plates, and the biofilms are grown in RPMI medium. In the second protocol, the biofilms are grown in 24-well plates but using GHAUM medium instead of yeast nitrogen base (YNB) agar.
Biofilm growth. Overnight cultures were washed in sterile 1ϫ PBS and diluted in the corresponding medium to an OD 600 of 0.3. Either 100 l or 1 ml of cells in the 96-well plate or the 24-well plate, respectively, was allowed to adhere for 1.5 h without agitation. The nonadhered cells were then washed with 1ϫ PBS, the same volume of fresh medium was added, plates were covered with a breathable seal, and biofilms were allowed to form for 48 h at 37°C with agitation (110 rpm), with a medium change after 24 h.
Antifungal treatment. Media were carefully aspirated from the 48-h-old biofilms without disrupting the biofilm structure. Biofilms were washed once with either 100 l or 1 ml of 1ϫ PBS, respectively, and treated with a 100 g/ml AMB solution in either RPMI or GHAUM medium for 24 h at 37°C, statically. AMB solutions were prepared from an 8 mg/ml stock in dimethyl sulfoxide (DMSO) so that the final concentration of DMSO in a working solution did not exceed 1.25%. For control biofilms, a corresponding amount of DMSO was added to the medium instead of the antifungal solution.
This step was either performed using the same volumes of antifungal solution as for biofilm growth as described by LaFleur et al. (8) or Li et al. (14) or the volume of antifungal was increased to fill the well to the top (350 l and 3 ml for 96-and 24-well plates, respectively).
Clinical isolates were first treated with a 64 g/ml AMB solution. Strains giving rise to colonies were then tested 5 times with 100 g/ml AMB.
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